Alcon’s stock lets you tap into the rapidly growing contact lenses and cataract surgery markets. Moreover, investors are set to benefit from the company’s expanding technological leadership. Alcon’s history enhances its appeal. The company was spun off by Novartis in early 2019. As we’ve said many times, spinoffs are the closest thing you can find to a sure thing, regardless of market ups and downs. In fact, study after study has shown that following an initial adjustment period, spinoffs tend to outperform comparable stocks for several years. All in all, we think Alcon offers investors two ways to profit. Not only does this spinoff provide exposure to rapidly expanding, worldwide demand for its products, but its global operations and research leadership enhance the possibility of a lucrative takeover bid. That interest could come from a rival or a global health-care giant. Our Successful Investor research team has drawn up this Inner Circle Spotlight report on Alcon to explain why we think the stock…